JAC Advance Access published online on March 12, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm018
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High tigecycline resistance in multidrug-resistant Acinetobacter baumannii
1 The Laboratory for Molecular Epidemiology and Antibiotic Research, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2 Division of Epidemiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Received 5 December 2006; returned 20 December 2006; revised 10 January 2007; accepted 10 January 2007
* Correspondence address. Department of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel. Tel: +972-3-692-5644; Fax: +972-3-697-4623; E-mail: shiri_nv{at}tasmc.health.gov.il
Objectives: Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our hospital and worldwide, raising the necessity of finding effective therapies. We aimed to evaluate the in vitro activity of tigecycline against MDR A. baumannii clones isolated before tigecycline was used in our institution.
Methods: Eighty-two unique patient clinical isolates of multidrug-resistant A. baumannii collected in 2003 were studied. Species identification and antibiotic susceptibilities were determined by Vitek-2. Tigecycline MIC was determined by Etest. Clonal relatedness was determined by PFGE.
Results: MDR A. baumannii possessed 19 different pulsotypes. Sixty-six percent of the isolates were resistant to tigecycline, 12% were intermediate and 22% were susceptible. The MIC50 and MIC90 of tigecycline were 16 and 32 mg/L, respectively, with a wide MIC range of 1–128 mg/L. Variability in MIC of tigecycline was evident between and within the same pulsotype.
Conclusions: We report here high resistance rates to tigecycline, and higher than previously described MICs, in multiple clones of MDR A. baumannii. As tigecycline represents a new treatment choice for infections caused by A. baumannii, these findings are worrisome.
Key Words: antibiotic resistance , glycylcyclines , MDR multiple clones , Etest
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Casal, F. Rodriguez, B. Johnson, E. Garduno, F. Tubau, R. O. de Lejarazu, A. Tenorio, M. J. Gimenez, R. Bartolome, C. Garcia-Rey, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J. Antimicrob. Chemother., July 1, 2009; 64(1): 69 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bean and D. W. Wareham Paradoxical effect of 1-(1-naphthylmethyl)-piperazine on resistance to tetracyclines in multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., February 1, 2009; 63(2): 349 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Jacoby AmpC {beta}-Lactamases Clin. Microbiol. Rev., January 1, 2009; 22(1): 161 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Hawkey The growing burden of antimicrobial resistance J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i1 - i9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Gallagher and H. M Rouse Tigecycline for the Treatment of Acinetobacter Infections: A Case Series Ann. Pharmacother., September 1, 2008; 42(9): 1188 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Capone, S. D'Arezzo, P. Visca, N. Petrosillo, and on behalf of the Gruppo Romano Acinetobacter bauma In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., August 1, 2008; 62(2): 422 - 423. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Moland, D. W. Craft, S.-g. Hong, S.-y. Kim, L. Hachmeister, S. D. Sayed, and K. S. Thomson In Vitro Activity of Tigecycline against Multidrug-Resistant Acinetobacter baumannii and Selection of Tigecycline-Amikacin Synergy Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2940 - 2942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Valentine, D. Contreras, S. Tan, L. J. Real, S. Chu, and H. H. Xu Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California J. Clin. Microbiol., August 1, 2008; 46(8): 2499 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Peleg, H. Seifert, and D. L. Paterson Acinetobacter baumannii: Emergence of a Successful Pathogen Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence J. Antimicrob. Chemother., July 1, 2008; 62(1): 45 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Loehfelm, N. R. Luke, and A. A. Campagnari Identification and Characterization of an Acinetobacter baumannii Biofilm-Associated Protein J. Bacteriol., February 1, 2008; 190(3): 1036 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yang and B J. Guglielmo Diagnosis and Treatment of Extended-Spectrum and AmpC {beta}-Lactamase-Producing Organisms Ann. Pharmacother., September 1, 2007; 41(9): 1427 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Thamlikitkul, S. Tiengrim, and C. Tribuddharat Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., July 1, 2007; 60(1): 177 - 178. [Full Text] [PDF]
|
|
|
|
|
|
S. Navon-Venezia, A. Leavitt, and Y. Carmeli High tigecycline resistance in multidrug-resistant Acinetobacter baumannii--authors' response J. Antimicrob. Chemother., July 1, 2007; 60(1): 178 - 179. [Full Text] [PDF]
|
|
|
|
|
|
D. Curcio and F. Fernandez Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective J. Antimicrob. Chemother., June 7, 2007; (2007) dkm202v1. [Full Text] [PDF]
|
|